Race, obesity, and risk for prostate cancer

By using data from the prospective SELECT trial (the Selenium and Vitamin E Cancer Prevention Trial, conducted between 2001 and 2011), researchers have been able to suggest that obesity is strongly associated with increased risk for prostate cancer diagnosis among African American males compared to non-Hispanic whites. … READ MORE …

PSMA ADC in treatment of mCRPC post-chemo and post-abiraterone and/or enzalutamide

Data from an open-label Phase II trial of PSMA ADC — a fully human IgG1 antibody conjugated to monomethyl auristatin E (MMAE) — suggests that this agent has activity in treatment of metastatic, castration-resistant prostate cancer (mCRPC) patients who have already progressed on abiraterone acetate and/or enzalutamide. … READ MORE …

Does sequencing of therapy affect outcomes of treatment with sipuleucel-T + ADT in high-risk disease?

We still have very little knowledge about whether early prostate cancer immunotherapy with sipuleucel-T (Provenge) or other forms of immunotherapy might be beneficial in the management of patients with high-risk prostate cancer. … READ MORE …

Intermittent vs. continuous ADT: the results of the ICELAND trial

The results of early, large, randomized trials of intermittent (IADT) vs. continuous androgen deprivation therapy (CADT) have provided conflicting results. However, one of the flaws in early trials was the failure to ensure that men enrolled into these trials all actually had an optimal initial response to androgen deprivation (ADT). … READ MORE …

Bill Manning’s blog: Part XI

Here is the latest of Bill’s blog posts. He, and we, hope it will be helpful to all those battling late stage prostate cancer. Click here for earlier parts if you missed them. … READ MORE …

Tasquinimod not sufficiently effective in mCRPC in major Phase III trial

According to a media release issued early today in Europe, Active Biotech and Ipsen have terminated the development of tasquinimod for the treatment of prostate cancer after the drug failed to show sufficient clinical benefit in a major Phase III clinical trial. … READ MORE …

Abstracts for annual meeting of the AUA now on line

Readers interested in looking through the 2,600 or so abstracts of papers to be presented at the upcoming annual meeting of the American Urological Association (AUA) can now do so. … READ MORE …

Follow

Get every new post delivered to your Inbox.

Join 1,263 other followers